In a filing, Adaptimmune Therapeutics Plc ADR revealed its Chief Executive Officer Rawcliffe Adrian unloaded Company’s shares for reported $20244.0 on Jan 17 ’24. In the deal valued at $0.67 per share,30,080 shares were sold. As a result of this transaction, Rawcliffe Adrian now holds 44,848 shares worth roughly $60993.280000000006.
Then, Bertrand William C JR sold 18,908 shares, generating $12,725 in total proceeds. Upon selling the shares at $0.67, the Chief Operating Officer now owns 7,785 shares.
Before that, Norry Elliot sold 18,276 shares. Adaptimmune Therapeutics Plc ADR shares valued at $12,300 were divested by the Chief Medical Officer at a price of $0.67 per share. As a result of the transaction, Norry Elliot now holds 7,785 shares, worth roughly $10587.6.
Bryan Garnier initiated its Adaptimmune Therapeutics Plc ADR [ADAP] rating to a Buy in a research note published on March 24, 2023; the price target was $3.60. A number of analysts have revised their coverage, including Guggenheim’s analysts, who increased its forecast for the stock in early January from “a Neutral” to “a Buy”. Mizuho also remained covering ADAP and has increased its forecast on November 09, 2022 with a “Buy” recommendation from previously “Neutral” rating. Barclays started covering the stock on May 28, 2021. It rated ADAP as “an Underweight”.
Price Performance Review of ADAP
On Monday, Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] saw its stock fall -0.73% to $1.36. Over the last five days, the stock has lost -7.48%. Adaptimmune Therapeutics Plc ADR shares have risen nearly 71.50% since the year began. Nevertheless, the stocks have risen 29.52% over the past one year. While a 52-week high of $2.05 was reached on 03/08/24, a 52-week low of $0.42 was recorded on 01/17/24. SMA at 50 days reached $1.3711, while 200 days put it at $0.8844. A total of 1.02 million shares were traded, compared to the trading of 1.64 million shares in the previous session.
Levels Of Support And Resistance For ADAP Stock
The 24-hour chart illustrates a support level at 1.3233, which if violated will result in even more drops to 1.2867. On the upside, there is a resistance level at 1.4033. A further resistance level may holdings at 1.4467. The Relative Strength Index (RSI) on the 14-day chart is 45.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0664, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.73%. Stochastics %K at 29.27% indicates the stock is a holding.
How much short interest is there in Adaptimmune Therapeutics Plc ADR?
A steep rise in short interest was recorded in Adaptimmune Therapeutics Plc ADR stocks on Mar 15, 2024, growing by 0.18 million shares to a total of 3.11 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 2.93 million shares. There was a rise of 5.79%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 2.89% of the overall stock float, the days-to-cover ratio (short ratio) rose to 1.55.
The most recent change occurred on April 22, 2020 when Mizuho began covering the stock and recommended ‘”a Neutral”‘ rating along with a $3 price target.
